PDF herunterladen
Aktuelle Neurologie 2012; 39(10): 546-552
DOI: 10.1055/s-0032-1331191
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Botulinumtoxin bei Kopfschmerzen

Botolinum Toxin for Headache
D. Holle
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen und Westdeutsches Kopfschmerzzentrum Essen
,
K. Rabe
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen und Westdeutsches Kopfschmerzzentrum Essen
,
M. Obermann
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen und Westdeutsches Kopfschmerzzentrum Essen
,
A. Straube
2   Klinik für Neurologie der Universität München und Oberbayerisches Kopfschmerzzentrum
,
M. Gerwig
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen und Westdeutsches Kopfschmerzzentrum Essen
,
H.-C. Diener
1   Universitätsklinik für Neurologie der Universität Duisburg-Essen und Westdeutsches Kopfschmerzzentrum Essen
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
03. Januar 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Bei chronischen Kopfschmerzerkrankungen ist die Wirksamkeit der zur Verfügung stehenden prophylaktischen Medikation oftmals unzureichend. Neue klinische Daten zeigen, dass Botulinumtoxin nicht nur bei muskulärer Überaktivität eingesetzt werden kann (z. B. bei Dystonie oder Spastik) sondern auch antinozizeptive Effekte besitzt. Für Onabotulinumtoxin A (Botox®) und eingeschränkt auch Abobotulinumtoxin A (Dysport®) liegen teilweise vielversprechende Ergebnisse für die Behandlung von Kopfschmerzerkrankungen vor. Bei Patienten mit chronischen Spannungskopfschmerzen sowie Patienten mit episodischer Migräne konnten wiederholt keine signifikanten Behandlungseffekte nachgewiesen werden. Bei Patienten mit chronischer Migräne mit und ohne begleitenden Medikamentenübergebrauch zeigte sich in verschiedenen Studien eine signifikante Abnahme der monatlichen Kopfschmerz- und Migränetage nach Injek­tion von Botulinumtoxin. Zudem zeigte sich eine deutliche Verbesserung der Lebensqualität. Die Therapie mit Botulinumtoxin war generell gut verträglich. Erste Studien zeigen auch eine gute Wirksamkeit von Botulinumtoxin in der Therapie der Trigeminusneuralgie. Bezüglich der Therapie trigeminoautonomer Kopfschmerzen liegen noch nicht genügend Daten vor, um diese abschließend beurteilen zu können.

Abstract

In many cases current prophylactic medication is not effective enough for treatment of chronic headache disorders. New data from controlled trials and case series suggest that botulinum toxin is effective not only for the treatment of muscular overactivity (e. g., dystonia or spasticity) but has also antinociceptive properties. Therefore, Onabotulinum toxin A (Botox®) and to a lesser extent Abobotulinum toxin A (Dysport®) show promising results regarding headache treatment. In patients with chronic tension type headache as well as in episodic migraneurs botulinum toxin was not effective for prophylactic therapy. Patients with chronic migraine with and without medication overuse showed a significant reduction of monthly headache and migraine days after injection of botulinum toxin. Additionally, a significant improvement of quality of life was observed. Injections of botulinum toxin were well tolerated. First studies report a prophylactic efficacy of botulinum toxin in the treatment of trigeminal neuralgia. With respect to trigeminoautonomic cephalagias more study data are needed for final evaluation.

Schlüsselwörter

Botulinumtoxin - chronische Migräne - Medikamenten­übergebrauch - Spannungskopfschmerz - Trigeminoautonome Kopfschmerzen

Keywords

botulinum toxin - chronic migraine - medication overuse - tension type headache - trigemino autonomic cephalagias
 

  • Literatur

  • 1 Kerner J. Das Fettgift oder die Fettsäure und ihre Wirkung auf den tierischen Organismus. 1822;
    PubMedGoogle Scholar
  • 2 Simpson LL. Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980; 212: 16-21
    PubMedGoogle Scholar
  • 3 Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 (Suppl. 01) S9-S15
    CrossrefPubMedGoogle Scholar
  • 4 Qerama E, Fuglsang-Frederiksen A, Jensen TS. The role of botulinum toxin in management of pain: an evidence-based review. Curr Opin Anaesthesiol 2010; 23: 602-610
    CrossrefPubMedGoogle Scholar
  • 5 Schulte-Mattler WJ, Wieser T, Zierz S. Treatment of tension-type headache with botulinum toxin: a pilot study. Eur J Med Res 1999; 4: 183-186
    PubMedGoogle Scholar
  • 6 Carruthers A, Langtry JA, Carruthers J et al. Improvement of tension-type headache when treating wrinkles with botulinum toxin A injections. Headache 1999; 39: 662-665
    CrossrefPubMedGoogle Scholar
  • 7 Erdemoglu AK, Varlibas A. The long-term efficacy and safety of botulinum toxin in refractory chronic tension-type headache. J Headache Pain 2007; 8: 294-300
    CrossrefPubMedGoogle Scholar
  • 8 Hamdy SM, Samir H, El-Sayed M et al. Botulinum toxin: could it be an effective treatment for chronic tension-type headache?. J Headache Pain 2009; 10: 27-34
    CrossrefPubMedGoogle Scholar
  • 9 Silberstein SD, Göbel H, Jensen R et al. Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia 2006; 26: 790-800
    CrossrefPubMedGoogle Scholar
  • 10 Mathew NT, Kailasam J, Meadors L. Predictors of response to botulinum toxin type A (BoNTA) in chronic daily headache. Headache 2008; 48: 194-200
    PubMedGoogle Scholar
  • 11 Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. JAMA 2012; 307: 1736-1745
    CrossrefPubMedGoogle Scholar
  • 12 Binder WJ, Brin MF, Blitzer A et al. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000; 123: 669-676
    CrossrefPubMedGoogle Scholar
  • 13 Saper JR, Mathew NT, Loder EW et al A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007; 8: 478-485
    CrossrefPubMedGoogle Scholar
  • 14 Elkind AH, O’Carroll P, Blumenfeld A et al. A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006; 7: 688-696
    CrossrefPubMedGoogle Scholar
  • 15 Relja M, Poole AC, Schoenen J et al. A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007; 27: 492-503
    CrossrefPubMedGoogle Scholar
  • 16 Aurora SK, Gawel M, Brandes JL et al Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007; 47: 486-499
    PubMedGoogle Scholar
  • 17 Mathew NT, Frishberg BM, Gawel M et al. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005; 45: 293-307
    CrossrefPubMedGoogle Scholar
  • 18 Freitag FG, Diamond S, Diamond M et al. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 2008; 48: 201-209
    PubMedGoogle Scholar
  • 19 Silberstein S, Mathew N, Saper J et al. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group. Headache 2000; 40: 445-450
    CrossrefPubMedGoogle Scholar
  • 20 Silberstein SD, Stark SR, Lucas SM et al. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2005; 80: 1126-1137
    CrossrefPubMedGoogle Scholar
  • 21 Dodick DW, Mauskop A, Elkind AH et al. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 2005; 45: 315-324
    CrossrefPubMedGoogle Scholar
  • 22 Petri S, Tölle T, Straube A et al. Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol 2009; 62: 204-211
    CrossrefPubMedGoogle Scholar
  • 23 Chankrachang S, Arayawichanont A, Poungvarin N et al. Prophylactic botulinum type A toxin complex (Dysport®) for migraine without aura. Headache 2011; 51: 52-63
    CrossrefPubMedGoogle Scholar
  • 24 Blumenfeld A, Silberstein SD, Dodick DW et al. Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program. Headache 2010; 50: 1406-1418
    CrossrefPubMedGoogle Scholar
  • 25 Olesen J, Bousser M-G, Diener H-C et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006; 26: 742-746
    CrossrefPubMedGoogle Scholar
  • 26 Aurora SK, Dodick DW, Turkel CC et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010; 30: 793-803
    CrossrefPubMedGoogle Scholar
  • 27 Diener HC, Dodick DW, Aurora SK et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010; 30: 804-814
    CrossrefPubMedGoogle Scholar
  • 28 Dodick DW, Turkel CC, DeGryse RE et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010; 50: 921-936
    CrossrefPubMedGoogle Scholar
  • 29 Silberstein S, Dodick D, Degryse R et al. The Percent of Chronic Migraine Patients who Responded to OnabotulinumtoxinA Treatment per Treatment Cycle in the PREEMPT Clinical Program. Neurology 2012; 78: 1001 64th American Academy of Neurology Annual Meeting, April 21-28, 2012
    PubMedGoogle Scholar
  • 30 Aurora SK, Winner P, Freeman MC et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-Week PREEMPT clinical program. Headache 2011; 51: 1358-1373
    CrossrefPubMedGoogle Scholar
  • 31 Lipton RB, Varon SF, Grosberg B et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011; 77: 1465-1472
    CrossrefPubMedGoogle Scholar
  • 32 Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006; 46: 1552-1564
    CrossrefPubMedGoogle Scholar
  • 33 Naumann M, Carruthers A, Carruthers J et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25: 2211-2218
    CrossrefPubMedGoogle Scholar
  • 34 Mathew P, Cutrer FM, Garza I. Cutaneous allodynia as a prognostic factor in the treatment of migraine with Botulinum toxin (abstract no PO-69). 52nd Annual Scientific Meeting of the American Headache Society; Jun 2010: 24-27 Los Angeles:
    Google Scholar
  • 35 Rothrock JF, Andress- Rothrock D, Hanlon C et al. Is onabotulinumtoxin A a cost effective therapy for chronic migraine? (abstract PS2-163). 15th Congress of the International Headache Society; June 2011: 23-26 Berlin:
    Google Scholar
  • 36 Diener HC. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-Week Pooled subgroup analysis of patients without medication overuse (Abstract). J Headache Pain 2012; [3rd European Headache and Migraine Trust International Congress – EHMTIC, September 20–23, 2012
    PubMedGoogle Scholar
  • 37 Sostak P, Krause P, Förderreuther S et al. Botulinum toxin type-A therapy in cluster headache: an open study. J Headache Pain 2007; 8: 236-241
    CrossrefPubMedGoogle Scholar
  • 38 Zabalza RJ. Sustained response to botulinum toxin in SUNCT syndrome. Cephalalgia 2012; 32: 869-872
    CrossrefPubMedGoogle Scholar
  • 39 Bohluli B, Motamedi MHK, Bagheri SC et al. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 47-50
    PubMedGoogle Scholar
  • 40 Zúñiga C, Díaz S, Piedimonte F et al. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008; 66: 500-503
    CrossrefPubMedGoogle Scholar
  • 41 Türk U, Ilhan S, Alp R et al. Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005; 28: 161-162
    CrossrefPubMedGoogle Scholar
  • 42 Piovesan EJ, Teive HG, Kowacs PA et al. An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology 2005; 65: 1306-1308
    CrossrefPubMedGoogle Scholar
  • 43 Göbel H, Lindner V, Krack P et al. Treatment of chronic tension-type headache with botulinum toxin. Cephalalgia. 1999 19. 455
    PubMedGoogle Scholar
  • 44 Rollnik JD, Tanneberger O, Schubert M et al. Treatment of tension-type headache with botulinum toxin type A: a double-blind, placebo-controlled study. Headache 2000; 40: 300-305
    CrossrefPubMedGoogle Scholar
  • 45 Schmitt WJ, Slowey E, Fravi N et al. Effect of botulinum toxin A injections in the treatment of chronic tension-type headache: a double-blind, placebo-controlled trial. Headache 2001; 41: 658-664
    CrossrefPubMedGoogle Scholar
  • 46 Padberg M, de Bruijn SFTM, de Haan RJ et al. Treatment of chronic tension-type headache with botulinum toxin: a double-blind, placebo-controlled clinical trial. Cephalalgia 2004; 24: 675-680
    CrossrefPubMedGoogle Scholar
  • 47 Schulte-Mattler WJ, Krack P. Treatment of chronic tension-type headache with botulinum toxin A: a randomized, double-blind, placebo-controlled multicenter study. Pain 2004; 109: 110-114
    CrossrefPubMedGoogle Scholar
  • 48 Straube A, Empl M, Ceballos-Baumann A et al. Pericranial injection of botulinum toxin type A (Dysport) for tension-type headache – a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 2008; 15: 205-213
    CrossrefPubMedGoogle Scholar
  • 49 Harden RN, Cottrill J, Gagnon CM et al. Botulinum toxin a in the treatment of chronic tension-type headache with cervical myofascial trigger points: a randomized, double-blind, placebo-controlled pilot study. Headache 2009; 49: 732-743
    CrossrefPubMedGoogle Scholar